CervoMed reports positive Phase 2b extension data for neflamapimod in DLB

CervoMed Inc.

Neflamapimod slowed clinical progression on CDR-SB vs old capsules (p<0.001) and vs placebo (p=0.003) over 16 weeks.
Mean CDR-SB improvement of 0.73 points with new capsules vs old; 40% relative reduction in clinically meaningful worsening.
Falls incidence reduced to 4% with new capsules vs 15.2% with old (p=0.025) in patients without AD co-pathology.
Improvement also seen on ADCS-CGIC (p=0.035 vs old capsules) and cognitive/fluctuation endpoints.
Company expects to complete full 32-week extension and engage FDA for Phase 3 plans later in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.